The technology company expands its services to streamline the clinical trial process with powerful technology
“Currently, the clinical trial process is slow and inefficient. Trials take 30-40% longer than expected due to poor recruitment, 15-40% of patients drop out before they finish and trial procedures are becoming increasingly complex,” said Brian Neman, CEO and co-founder of Sanguine. “There is a huge need in the market to solve these issues and make the clinical trial process faster and more robust. At Sanguine, we are committed to advancing biomedical research by providing a comprehensive solution that spans the entire clinical development process.”